49 results about "Mean arterial pressure" patented technology

The invention discloses a method for measuring vascular elasticity modulus and blood pressure based on LC-OCT hyperelastic modeling, which comprises the following steps: accurately capturing dynamic deformation of blood vessels through high-resolution three-dimensional imaging and Doppler blood flow detection of LC-OCT, calculating the elasticity modulus (error is less than or equal to + / -5%) by combining a Fung model, and constructing a mixed blood pressure prediction model based on a theory-data dual-drive framework. High-precision inversion (MAE < = 5.1 mmHg) of systolic pressure, diastolic pressure and average arterial pressure is achieved, and dynamic transfer learning is adopted to adapt to the blood vessel characteristic differences of different crowds. The method has the advantages that blood vessel full-dimension characterization is achieved through multi-mode LC-OCT, dynamic transfer learning adapts to the difference of healthy / sick people, a theory-data dual-drive model gives consideration to physical interpretability and prediction precision, and a high-precision solution is provided for early diagnosis and personalized treatment of hypertension.

Systems and methods for non-invasively measuring intracranial in accordance with embodiments of the invention are illustrated. One embodiment includes a method for estimating an intracranial pressure of a patient, including introducing a tracer into the blood of a patient, recording, using an imaging device, the traversal of the tracer through a brain of the patient as a kinetic curve, estimating a mean transit time (MTT) of the tracer through the brain of the patient based on the kinetic curve, measuring a mean arterial pressure (MAP) of the patient, calculating an intracranial pressure index as MAP−Ck / MTT, where C is a constant to scale proportional relationships based on healthy patient population characteristics, and k is a constant in pressure / time, and providing the intracranial pressure index. In various embodiments, regions of the brain unaffected by transient vascular abnormalities are identified and are used for data collection.

The method for monitoring parameters of a patient during surgery with extracorporeal circulation serves to estimate the presence of AKI risk and comprises calculating a dynamic global index of AKI risk as a logistic regression deriving from a static AKI risk index and a dynamic index of AKI risk. The value and / or the time trend of such global index of AKI risk can be advantageously displayed on a monitor during the surgery. The dynamic AKI risk index is calculated at least on the basis of the extracorporeal circulation time, the minimum level of oxygen supply and the exposure time to oxygen supply below a critical threshold which are measured or determined repeatedly during surgery. Preferably, the dynamic AKI risk index is also calculated on the basis of the minimum mean arterial pressure during surgery and / or the maximum concentration of lactate in the blood during surgery and / or the minimum hematocrit during surgery and / or the fact that the patient has been subjected to transfusion(s) during the extracorporeal circulation.

In some examples, a method includes receiving a signal indicative of a blood pressure of a patient and identifying at least one first portion of the signal comprising a first characteristic of the signal exceeding a first threshold. The method also includes identifying at least one first portion of the signal comprising a second characteristic of the signal exceeding a second threshold, the first characteristic being different than the second characteristic. The method further includes determining a filtered signal indicative of the blood pressure of the patient by excluding the at least one first portion and the at least one second portion from the signal. The method includes determining a set of mean arterial pressure values based on the filtered signal and determining an autoregulation status of the patient based on the set of mean arterial pressure values.

The invention discloses a method and a system for predicting preeclampsia risk of a pregnant woman based on computer implementation. The method integrates the concentration level of vitamin D (especially 25-hydroxyvitamin D) in serum of pregnant women, angiogenesis biomarkers (such as sFlt-1 / PlGF ratio), conventional clinical indexes (such as mean arterial pressure and body mass index) and personal medical history data. A machine learning algorithm (such as a random forest or a gradient lifting model) is adopted to carry out weighted analysis on the multi-dimensional data, and a dynamic and high-precision prediction model is constructed. The system comprises a data acquisition module, an intelligent prediction module and a clinical decision support module, and can provide real-time risk assessment and personalized intervention suggestions (such as a vitamin D supplement scheme) for medical staff, so that early warning and effective management of preeclampsia are realized, and the risk of pregnancy outcome caused by maternal and infant poor pregnancy is reduced.

An optical-based oscillometric blood pressure measurement device includes a cuff, which is pneumatically connected to an inflation / deflation unit and electronically connected to a pressure detection unit. It also includes light emission diode and photodiode pairs, and a volume detection unit that converts the plethysmogram received by the photodiode to the optical oscilloetrygram as the artery volume signal. Its control unit determines inflation / deflation slopes and the start / stop pressures and accurately traces the prescribed controller set point. Its extraction unit measures the systolic, diastolic, and mean arterial pressure accurately.

A method for evaluating a patient's extracorporeal membrane oxygenation (ECMO) operation status includes: collecting the patient's oxygen saturation data, lactate data, and oxygen partial pressure data or mean arterial pressure data; based on oxygen partial pressure data, obtaining the oxygen partial pressure classification value through a pre-trained oxygen partial pressure classifier, or based on the mean arterial pressure data, obtaining the mean arterial pressure classification value through a pre-trained mean arterial pressure classifier; based on blood oxygen saturation data, obtaining the blood oxygen saturation classification value through the pre-trained blood oxygen saturation classifier; based on the lactate data, obtaining the lactate level classification value through the pre-trained lactate level classifier; determining the patient's ECMO operation score based on the blood oxygen saturation classification value, lactate level classification value, and oxygen partial pressure classification value or mean arterial pressure classification value.

An apparatus for estimating bio-information is provided. The apparatus for estimating bio-information includes: a pulse wave sensor configured to measure a pulse wave signal from an object; a force sensor configured to measure force exerted between the object and the pulse wave sensor; and a processor configured to obtain an oscillogram by using the pulse wave signal and the force, to determine a first mean arterial pressure (MAP) based on the obtained oscillogram, to extract additional information in an interval preceding a point of the first MAP of the oscillogram, to obtain a second MAP based on the first MAP and the additional information, and to estimate bio-information based on the obtained second MAP.

The present invention relates to a water intoxication prevention system for hysteroscopic resection, belonging to the technical field of medical equipment. The water intoxication prevention system includes: a data acquisition module for obtaining surgical data information related to hysteroscopic resection; a data processing module for receiving and processing the surgical data information obtained by the data acquisition module, and calculating and real-time updating the water intoxication risk value. The data acquisition module includes an input unit and a monitoring unit. The data processing module is configured to: preliminarily calculate the water intoxication risk value according to the estimated surgical duration, the type of distending medium to be used, the scheduled distending pressure, and the measured mean arterial pressure obtained by the input unit, so as to obtain an expected risk value corresponding to the estimated surgical duration; dynamically adjust the preliminarily calculated water intoxication risk value according to the perfusion fluid volume, blood oxygen saturation, serum sodium ion level, and the current surgical duration obtained by the monitoring unit, so as to obtain a dynamic risk value corresponding to the current surgical duration.

This invention relates to the field of multi-organ dysfunction (MOD) early warning technology, specifically to an MOD early warning method for patients with severe burns. The method includes the following steps: acquiring heart rate, mean arterial pressure, respiratory rate, blood oxygen saturation, lactate concentration, and urine output per unit time; calculating the rate of lactate change at adjacent time points to form a sequence; comparing the rate of change across time intervals to obtain the difference in change; combining heart rate and blood oxygen saturation to calculate circulatory load; and counting the number of early warning triggers that meet risk conditions. In this invention, by calculating the rate of change of lactate concentration at adjacent time points and combining it with interval direction statistics, tissue metabolic changes show trend characteristics; the rate of change of urine output combined with mean arterial pressure forms a record of renal perfusion changes, providing a continuous characterization of perfusion status; heart rate and blood oxygen saturation are used to calculate circulatory load; multiple physiological signals are linked for judgment; and recurring abnormalities are expressed through the number of triggers. This improves the stability and predictability of MOD risk identification in critically burned patients.

A continuous blood pressure measurement device includes a cuff airbag pneumatically connected to an inflation / deflation unit and a pressure detection unit. The device also comprises at least one light-emitting diode, at least one photodiode, and a volume detection unit configured to convert photoplethysmogram signals into arterial volume signals. A control unit precisely tracks a predefined setpoint to achieve arterial unloading based on a volume compensation method. An extraction unit reconstructs a high-fidelity arterial blood pressure waveform and accurately determines systolic, diastolic, mean arterial pressures, and heart rate.

Methods and apparatuses for noninvasive, continuous blood pressure estimation using one or more pressure sensors integrated into footwear, such as slippers, shoes, insoles, or padded socks. The sensors measure time-varying plantar pressure signals that include both weight-bearing and cardiovascular components. When a wearer stands or walks, the body weight load compresses underlying plantar arteries against the sensor surface, creating an oscillometric interaction between externally applied mechanical pressure and internal arterial blood pressure. Signal processing extracts blood-pressure-induced pulsatile modulations from the measured plantar pressure signal and estimates systolic blood pressure, diastolic blood pressure, and mean arterial pressure by analyzing the envelope of these modulations as a function of the applied weight-bearing pressure. The system operates passively and continuously without an inflatable cuff, without requiring user intervention, and without interrupting the wearer's daily activities.

A hemodynamic monitoring system monitors arterial blood pressure of a patient and provides a warning to medical personnel of a predicted future hypotensive event of the patient. Sensed hemodynamic data representative of an arterial pressure waveform of the patient is received by a hemodynamic monitor. The received hemodynamic data is shifted based on a difference between a standard mean arterial pressure (MAP) threshold for hypotension and an adjusted MAP threshold for hypotension to produce adjusted hemodynamic data. A waveform analysis of the adjusted hemodynamic data is performed and a risk score representative of a probability of a future hypotensive event of the patient is determined based on the waveform analysis. In response to the risk score satisfying a predetermined risk criterion, an sensory alert is invoked to produce a sensory signal.

This invention discloses an endothelin A receptor antagonist-albumin fusion protein and its application in preventing and treating hypotension during anesthesia induction. The fusion protein is formed by chemically coupling BQ-123 with human serum albumin (HSA). BQFu significantly enhances its antihypertensive effect by prolonging the half-life of BQ-123 and improving plasma stability. Experiments show that BQFu dose-dependently inhibits the decrease in mean arterial pressure (MAP) in a propofol-induced hypotension model, with a sustained and stable effect in the high-dose group (30 mpk), shortening the recovery time to 20.8 ± 10.5 min, while maintaining BQ-123 activity. This invention provides a long-acting and safe prevention and treatment strategy for hypotension during anesthesia induction.

Systems and methods for non-invasively measuring intracranial in accordance with embodiments of the invention are illustrated. One embodiment includes a method for estimating an intracranial pressure of a patient, including introducing a tracer into the blood of a patient, recording, using an imaging device, the traversal of the tracer through a brain of the patient as a kinetic curve, estimating a mean transit time (MTT) of the tracer through the brain of the patient based on the kinetic curve, measuring a mean arterial pressure (MAP) of the patient, calculating an intracranial pressure index as MAP−Ck / MTT, where C is a constant to scale proportional relationships based on healthy patient population characteristics, and k is a constant in pressure / time, and providing the intracranial pressure index. In various embodiments, regions of the brain unaffected by transient vascular abnormalities are identified and are used for data collection.

Provided herein are compositions, such as suitable for subcutaneous administration, and methods for modulating mean arterial pressure (MAP) in an individual using a hybrid V1A receptor agonist-antagonist.

Provided is a method for diagnosing or predicting preeclampsia in a pregnant woman or determining if a pregnant woman has a risk of preeclampsia, comprising: a) obtaining at least one (such as two or more) maternal or fetal parameter or factor of the pregnant woman, selected from a group comprising: (i) one or more of mean artery pressure (MAP), BMIsampling, ΔBMI, Gestational age and ΔBMI / GA; (ii) Maternal age; (iii) one or more of Urinary protein level and the ratio of Urinary protein level (such as Urine Total Protein (UTP) ) / Urinary Creatinine level (Cre) (UTP / Cre); (iv) one or more of preeclampsia in previous pregnancy (PEhis) and having received antihypertensive medication (Antihyper); and (v) any combination of (i) - (iv), b) determining if the urine of said pregnant woman contains misfolded proteins or misfolded protein aggregates, and c) combining the at least one maternal or fetal parameter or factor obtained in step a) and the content level of misfolded proteins or misfolded protein aggregates in the urine of said pregnant woman to diagnose or predict preeclampsia or determine the risk of preeclampsia.

This invention provides a method, system, and device for monitoring anesthesia status based on multi-source physiological signal analysis, relating to the field of medical monitoring technology. The method includes: acquiring electroencephalogram (EEG) signals, real-time heart rate, heart rate variability coefficient, and real-time mean arterial pressure of a patient under anesthesia; performing preliminary filtering of the EEG signals using high-pass and low-pass filters, and normalizing the amplitude of the EEG signals to obtain new EEG signals; acquiring several modal functions; extracting multidimensional features from each modal function; forming a feature set; training a machine learning model using the feature set, and using the trained machine learning model to predict the patient's anesthesia status in real time, outputting anesthesia stage classification results; determining the comprehensive stability coefficient of the anesthesia status; determining the anesthesia depth instability fluctuation coefficient; and performing anesthesia status monitoring. According to this invention, the accuracy of anesthesia status monitoring can be improved.

The present application relates to the technical field of body position management, in particular to an aorta postoperative patient body position intelligent management pad system based on hemodynamic parameters, which introduces classification and regression tree to organize mean arterial pressure interval, systolic pressure interval, blood pressure change rate sign, exponential weighted deviation interval, cumulative deviation state, uncertainty level and body position maintenance time interval into ordered conditional branches, explicitly injects safety priority logic into body position sorting process, makes high-risk signals obtain higher weight proportion in decision chain, maps body position enumeration into discrete state by limited state machine and introduces interval member guard count and locking time, so that body position switching is no longer instantaneous judgment but triggered after continuous condition satisfaction, and the overall process forms a continuous traceable closed loop under the multi-layer superposition of rule chain, cost weight, state transition and path constraint, the body position execution process remains stability in blood flow fluctuation stage, and nursing operation consistency and controllability are significantly improved.

The present invention discloses a nucleic acid molecule for inhibiting PNO1 gene expression, as well as related products and uses. The nucleic acid molecule comprises double-stranded RNA or shRNA. The present invention utilizes an RNAi method to obtain siRNA, or a nucleic acid construct, viral particle, or cell containing the siRNA sequence. By downregulating PNO1 gene expression, the siRNA can effectively inhibit and significantly reduce systolic blood pressure, diastolic blood pressure, mean arterial pressure, pulse wave velocity, and vascular wall thickness in the abdominal aorta, thereby preventing and / or treating hypertension. The siRNA can be used in drugs for treating hypertension, opening up new avenues for hypertension treatment.

Methods, systems, and computer-readable medium for determining a systemic vascular resistance (SVR), by receiving a systolic blood pressure (SBP) and a diastolic blood pressure (DBP) from one or more blood pressure devices, receiving a first bioimpedance from a first electrode and a second bioimpedance from a second electrode, determining a stroke volume based on a difference between the first bioimpedance and the second bioimpedance, determining a mean arterial pressure (MAP) based on the SBP and the DBP, receiving a heart rate, determining a cardiac output based on the heart rate and the stroke volume, determining a first value based on a right atrial pressure (RAP) or central venous pressure (CVP) and the map, determining a second value based on the first value and the cardiac output, and determining a SVR based on the second value and a factor.

Methods, systems, and computer-readable medium for determining a systemic vascular resistance (SVR), by receiving a systolic blood pressure (SBP) and a diastolic blood pressure (DPB) from a calibrated photoplethysmography (PPG) device, receiving a pulse transit time (PTT) from the PPG device, determining a stroke volume based on the PTT, determining a mean arterial pressure (MAP) based on the SBP and the DBP, receiving a heart rate, determining a cardiac output based on the heart rate and the stroke volume, determining a first value based on a right atrial pressure (RAP) or central venous pressure (CVP) and the map, determining a second value based on the first value and the cardiac output, and determining a SVR based on the second value and a factor.

An example method includes outputting, toward a blood vessel of a subject during a cardiac cycle of the subject, an ultrasound signal; detecting, from the blood vessel of the subject during the cardiac cycle of the subject, a reflection of the ultrasound signal; and determining a normalized distension of the blood vessel of the subject during the cardiac cycle by analyzing the reflection of the ultrasound signal. The example method further includes determining a blood pressure of the subject by adding a mean arterial pressure of the subject to a product of the normalized distension of the blood vessel and a pulse pressure of the subject. In addition, the example method includes outputting an indication of the blood pressure.

This invention discloses a simulated upper arm artery blood pressure ultrasound phantom device and a method for verifying ultrasound blood pressure measurement technology. The device includes: simulated blood circulating through tubing via a peristaltic pump from a buffer tank, a flow meter, the simulated upper arm artery blood pressure ultrasound phantom, to a reservoir. The peristaltic pump and buffer tank work together to achieve constant flow and pulsating modes. An airbag pressurizer is connected to the upper air chamber of the reservoir to pressurize the tubing, providing a base pressure simulating the human mean arterial pressure. The pulsating mode of the peristaltic pump simulates the pulsating pressure changes within the systolic and diastolic pressure ranges of human blood pressure, and these changes are displayed and recorded in real time via a pressure transmitter and a connected digital oscilloscope. The simulated upper arm artery blood pressure ultrasound phantom allows the internally implanted simulated arteries to radially expand and contract with pressure pulsation, simulating the dynamic behavior of the human upper arm artery, thus verifying the ultrasound blood pressure measurement technology.

This invention relates to the field of medical artificial intelligence technology and discloses a method for predicting the resuscitation status of patients with septic shock. The method includes: acquiring state parameters of the patient with septic shock; preprocessing the acquired state parameters to obtain input parameters; obtaining training data based on a critical care database; training a prediction model using the training data; inputting the input parameters into the trained prediction model to obtain a first prediction probability; and performing binary classification on the first prediction probability to obtain a final prediction result. The state parameters include target parameters, which include multiple variables such as mean arterial pressure, arterial blood lactate, base excess, pH, bicarbonate, and anion gap. This method and system for predicting the resuscitation status of patients with septic shock can prospectively output the overall probability of achieving resuscitation targets at the 6th hour using conventionally available multidimensional clinical information within 0-2 hours after admission to the ICU.

A hemodynamic monitoring system monitors arterial blood pressure of a patient and provides a warning to medical personnel of a predicted future hypotensive event of the patient. Waveform analysis is performed on sensed hemodynamic data representative of an arterial pressure waveform of the patient to determine a plurality of hypotension analysis parameters predictive of a future hypotensive event of the patient. A set of transformed hypotension analysis parameters is generated based on the hypotension analysis parameters and a standard mean arterial pressure (MAP) threshold for hypotension and mean and standard deviation values of the hypotension analysis parameters at an adjusted MAP threshold for hypotension. A risk score representative of a probability of a future hypotensive event of the patient is determined based on the set of transformed hypotension analysis parameters. A sensory alarm is invoked to produce a sensory signal in response to the risk score satisfying a predetermined risk criterion.

The present invention relates to a method for prognosis, prediction, risk assessment and / or risk stratification of preeclampsia in a pregnant subject comprising determining the level of soluble fms-like tyrosine kinase-1 (sFlt-1) or fragments thereof in a sample that has been isolated from the pregnant subject. The invention also relates to a method for prognosis, prediction, risk assessment and / or risk stratification of premature preeclampsia in a pregnant subject. The invention also relates to sFlt-1 and PIGF, optionally combined measurements in combination with consideration of one or more additional factors selected from pregnant and lying-in woman age, body mass index, uterine artery Doppler measurements and / or mean arterial pressure (MAP). The invention also relates to a kit for carrying out the method of the invention comprising a detection reagent for determining the level of sFlt-1 or a fragment thereof in a sample from a subject, and optionally for determining the level of at least one additional biomarker as described herein in a sample from a subject.

The invention provides application of tilianin in preparation of a medicine for preventing and / or treating ejection fraction retention type heart failure, and belongs to the technical field of biological medicines. The invention discloses application of tilianin in preparation of a medicine for preventing and / or treating ejection fraction retention type heart failure. Experiments show that tilianin has the effects of reducing mean arterial pressure, improving left ventricular diastolic dysfunction, protecting the heart and relieving liver injury. Therefore, tilianin has the efficacy of improving, preventing and / or treating ejection fraction retention type heart failure.

Devices, methods, and wearable devices for estimating blood pressure are disclosed. A device for estimating blood pressure according to an exemplary embodiment of the present disclosure includes: a pulse wave sensor configured to measure a pulse wave signal from a subject; and a processor configured to: obtain a first feature and a heart rate based on the pulse wave signal, estimate a mean arterial pressure (MAP) and a pulse pressure (PP) based on the first feature and the heart rate, and estimate a first blood pressure based on the MAP and the PP.

The present invention discloses the use of the AP2A1 gene in the preparation of a product for the prevention and treatment of hypertension. The present invention found that AP2A1 expression levels were significantly elevated in hypertensive rat models. Further, inhibiting AP2A1 expression in these rat models significantly reduced abdominal aorta systolic and diastolic blood pressures, mean arterial pressure, vascular wall thickness, and pulse wave velocity, thereby improving the hypertensive phenotype. This indicates that AP2A1 has a role in regulating hypertension and can serve as a target, which is of great significance for the future development of drugs and the prevention and treatment of hypertension.